(2S,3S)-2-azaniumyl-3-ethoxybutanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3S)-2-azaniumyl-3-ethoxybutanoate
• 化学式: C6H13NO3
• 分子量: 147.17
• InChiKey: LULHTUNPBBMNSJ-WHFBIAKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099274A1

  公开（公告）日：2003-12-04

  Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

  丙型肝炎病毒抑制剂公开了具有以下通式：其中R1、R2、R3、R'、B、Y和X在描述中有所描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Wang Alan Xiangdong

  公开号：US20090274656A1

  公开（公告）日：2009-11-05

  Hepatitis C virus inhibitors are disclosed having the general formula: wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  本发明揭示了一种具有一般式的丙型肝炎病毒抑制剂：其中R1、R2、R3、R'、B、Y和X在说明书中有所描述。还揭示了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• Hepatitis C Virus Inhibitors
  申请人：Wang Xiangdong Alan

  公开号：US20110311482A1

  公开（公告）日：2011-12-22

  Hepatitis C virus inhibitors are disclosed having the general formula: wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  本发明公开了具有下列一般式的丙型肝炎病毒抑制剂：其中R1、R2、R3、R'、B、Y和X在说明书中有所描述。还公开了包含该化合物的组合物和使用该化合物抑制HCV的方法。
• Spergualin-related compounds, processes for the preparation thereof and their use as medicaments
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：EP0105193A2

  公开（公告）日：1984-04-11

  This invention relates to novel spergualin-related compounds of the formula (I) wherein R1 represents a hydrogen atom, a hydroxyl group, or an aliphatic acyloxy group with 1 to 10 carbon atoms; R2 represents a residue of an a- or ω-amino acid remaining after removing one of the hydrogen atoms from the a- or ω-amino group and the hydroxyl group from the a-carboxyl group with the proviso that R2 does not include a residue of a-hydroxyglycine, said R2 being attached to the adjacent carbonyl group and amino group by amide bonds; and m denotes an integer of 4 to 6, and their physiologically acceptable salts, and to a process for preparing the same. The compounds according to the present invention exhibit high stability and antitumor activity.

  本发明涉及式 (I) 的新型 spergualin 相关化合物 其中 R1 代表氢原子、羟基或具有 1 至 10 个碳原子的脂肪族酰氧基；R2 代表从 a-或 ω-氨基中去除一个氢原子和从 a-羧基中去除羟基后剩余的 a-或 ω-氨基酸残基，但 R2 不包括 a-羟基甘氨酸残基，所述 R2 通过酰胺键连接到相邻的羰基和氨基上；和 m 表示 4 至 6 的整数，以及它们的生理上可接受的盐和制备它们的工艺。本发明的化合物具有高稳定性和抗肿瘤活性。
• Histargin-related compounds, a process for their preparation and their use as medicaments
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：EP0175180A1

  公开（公告）日：1986-03-26

  The present invention relates to compounds of the formula wherein A is a residual group obtained by removing one hydrogen atom from the alpha-amino group in an alpha-amino acid (excluding arginine) or a lower alkyl ester thereof; R is a hydrogen atom or a lower alkyl group, or a salt thereof, and to a process for the preparation of these compounds. The compounds are capable of inhibiting the action of angiotensin converting enzyme and can therefore be used as anti-hypertensive agents.

  本发明涉及式中 A 是通过从α-氨基酸（不包括精氨酸）或其低级烷基酯中α-氨基去掉一个氢原子而得到的残基；R 是氢原子或低级烷基或其盐的化合物，以及制备这些化合物的工艺。 这些化合物能够抑制血管紧张素转换酶的作用，因此可用作抗高血压药。